Regen Biopharma Inc (RGBP) Stock Price & Analysis
Regen Biopharma Inc (RGBP) rose 0.00% to USD 0 as of June 10, 2026 at 02:13 UTC, according to Nexqual real-time market data.
RGBP last closed at USD 0; the session ranged USD 0–0 on volume of 22,605,050 shares. Market capitalization is $102,391, with a 52-week range of USD 0–0.12 (OID). Source: Nexqual, June 10, 2026 at 02:13 UTC.
Key Statistics (as of June 10, 2026 at 02:13 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0.12 |
| Volume | 22,605,050 shares |
| Market Cap | $102,391 |
| Exchange | OID |
Technical Analysis (RGBP)
Nexqual's technical model rates RGBP "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 02:13 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.54 (neutral) |
| vs SMA50 | Below (USD 0) |
| MACD | -0 (negative) |
Analyst Ratings (RGBP)
Wall Street analysts rate RGBP "None", per Nexqual as of June 10, 2026 at 02:13 UTC.
| Consensus Rating | None |
|---|
Earnings (RGBP)
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financials & Fundamentals (RGBP)
| Total Revenue | $236,560 |
|---|---|
| Revenue Growth (YoY) | +0.00% |
| Gross Margin | +100.00% |
| Operating Margin | -260.24% |
| Profit Margin | +0.00% |
| Current Ratio | 0.05 |
| Total Cash | $271 |
| Total Debt | $959,146 |
| Free Cash Flow | $-436,287 |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Financial Health Score (RGBP)
Nexqual rates Regen Biopharma Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:13 UTC.
| Growth | Mixed — Revenue +0.0% YoY (latest Q), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $271 cash, no debt |
| Cash Flow | Weak — FCF negative: -$436K, burning cash |
| Efficiency | Mixed — No data |
Ownership (RGBP)
| Insider Ownership | +9.92% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 511.96M |
| Float | 465.70M |
Source: Nexqual, June 10, 2026 at 02:13 UTC.
Leadership (RGBP)
Regen Biopharma Inc is led by David Raymond Koos DBA (age 64), Chairman, CEO, President, Acting CFO, Secretary & Treasurer, per Nexqual as of June 10, 2026 at 02:13 UTC.
| Chairman, CEO, President, Acting CFO, Secretary & Treasurer | David Raymond Koos DBA (age 64) |
|---|
From Regen Biopharma Inc's Latest SEC 10-K Filing (filed 2025-12-30)
Key Strengths & Strategy (as disclosed to the SEC)
- After testing in animals, an Investigational New Drug Application ("IND") must be filed with the FDA to obtain authorization for human testing.
- No action can be taken to market any therapeutic product in the United States until an appropriate New Drug Application ("NDA") or Biologic License Application ("BLA") or has been approved by the FDA.
- The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator.   DiffronC: This drug is intended to use our proprietary siRNA in vivo to inhibit cancer growth and activate T cells.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RGBPP | Regen Biopharma, Inc. | USD 0 | ▲ 0% |
| GGII | Green Globe International, Inc. | USD 0 | ▲ 0% |
| TGGI | Trans Global Group, Inc. | USD 0 | ▲ 0% |
| KYNC | KYN Capital Group, Inc. | USD 0 | ▲ 0% |
| WDLF | Decentral Life, Inc. | USD 0 | ▼ 25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:13 UTC. This page is informational and not investment advice.